PAP
SLNO

Persistent Asset Partners’s Soleno Therapeutics SLNO Stock Holding History

Persistent Asset Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-230
Closed -$12.8K – 442
2025
Q3 		$12.8K Buy
+230
New +$17.1K 0.01% 212
2025
Q2 		– Sell
-533
Closed -$12.7K – 233
2025
Q1 		$12.7K Buy
533
+215
+68% +$10.5K 0.01% 154
2024
Q4 		$130K Buy
+318
New +$16.5K 0.11% 98

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Persistent Asset Partners's SLNO Position: Q1 2026 in Review

Persistent Asset Partners sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 7,416 shares — an estimated $343K sold.

Persistent Asset Partners first reported a position in SLNO in Q4 2024 and held it in 5 quarters. The position peaked at $5.47M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Persistent Asset Partners reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 7,416 Soleno Therapeutics shares in Q1 2026, an estimated $343K.
  • Persistent Asset Partners first reported a position in Soleno Therapeutics in Q4 2024 and held it in 5 quarters.
  • Persistent Asset Partners's Soleno Therapeutics position peaked at $5.47M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.